NCT03796260View on ClinicalTrials.gov

A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 9, 2019

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

Entrectinib Test Formulation (F1)

Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.

DRUG

Entrectinib Reference Formulation (F06)

Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.

Trial Locations (1)

32117

Covance Research Unit - Daytona, Daytona Beach

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT03796260 - A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants | Biotech Hunter | Biotech Hunter